This document is a patent application (US20260083841A1) filed with the USPTO on September 14, 2023, detailing a pharmaceutical composition for stabilizing bispecific antigen-binding molecules. The invention proposes a formulation that includes at least one buffer agent, at least one saccharide, and a stabilizing agent selected from Ethylenediaminetetraacetic acid (EDTA), Diethylenetriaminepentetic acid (DTPA), and citric acid. The goal is to maintain the stability of these molecules even at higher concentrations, which is crucial for therapeutic applications.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on pharmaceutical companies. However, it signals potential future developments in drug formulation and intellectual property within the biopharmaceutical sector. Companies involved in the development or manufacturing of bispecific antibodies should be aware of this patent filing as it may affect their own research, development, and patent strategies.